Five decades of clinical assessment of whole-sporozoite malaria vaccines
In 1967, pioneering work by Ruth Nussenzweig demonstrated for the first time that irradiated sporozoites of the rodent malaria parasite Plasmodium berghei protected mice against a challenge with infectious parasites of the same species. This remarkable finding opened up entirely new prospects of eff...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.977472/full |
| _version_ | 1798002201744900096 |
|---|---|
| author | Helena Nunes-Cabaço Diana Moita Miguel Prudêncio |
| author_facet | Helena Nunes-Cabaço Diana Moita Miguel Prudêncio |
| author_sort | Helena Nunes-Cabaço |
| collection | DOAJ |
| description | In 1967, pioneering work by Ruth Nussenzweig demonstrated for the first time that irradiated sporozoites of the rodent malaria parasite Plasmodium berghei protected mice against a challenge with infectious parasites of the same species. This remarkable finding opened up entirely new prospects of effective vaccination against malaria using attenuated sporozoites as immunization agents. The potential for whole-sporozoite-based immunization in humans was established in a clinical study in 1973, when a volunteer exposed to X-irradiated P. falciparum sporozoites was found to be protected against malaria following challenge with a homologous strain of this parasite. Nearly five decades later, much has been achieved in the field of whole-sporozoite malaria vaccination, and multiple reports on the clinical evaluation of such candidates have emerged. However, this process has known different paces before and after the turn of the century. While only a few clinical studies were published in the 1970’s, 1980’s and 1990’s, remarkable progress was made in the 2000’s and beyond. This article reviews the history of the clinical assessment of whole-sporozoite malaria vaccines over the last forty-nine years, highlighting the impressive achievements made over the last few years, and discussing some of the challenges ahead. |
| first_indexed | 2024-04-11T11:48:22Z |
| format | Article |
| id | doaj.art-11249ec3187d4489a54059bc2e03e71c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T11:48:22Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-11249ec3187d4489a54059bc2e03e71c2022-12-22T04:25:27ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-09-011310.3389/fimmu.2022.977472977472Five decades of clinical assessment of whole-sporozoite malaria vaccinesHelena Nunes-CabaçoDiana MoitaMiguel PrudêncioIn 1967, pioneering work by Ruth Nussenzweig demonstrated for the first time that irradiated sporozoites of the rodent malaria parasite Plasmodium berghei protected mice against a challenge with infectious parasites of the same species. This remarkable finding opened up entirely new prospects of effective vaccination against malaria using attenuated sporozoites as immunization agents. The potential for whole-sporozoite-based immunization in humans was established in a clinical study in 1973, when a volunteer exposed to X-irradiated P. falciparum sporozoites was found to be protected against malaria following challenge with a homologous strain of this parasite. Nearly five decades later, much has been achieved in the field of whole-sporozoite malaria vaccination, and multiple reports on the clinical evaluation of such candidates have emerged. However, this process has known different paces before and after the turn of the century. While only a few clinical studies were published in the 1970’s, 1980’s and 1990’s, remarkable progress was made in the 2000’s and beyond. This article reviews the history of the clinical assessment of whole-sporozoite malaria vaccines over the last forty-nine years, highlighting the impressive achievements made over the last few years, and discussing some of the challenges ahead.https://www.frontiersin.org/articles/10.3389/fimmu.2022.977472/fullvaccineplasmodiumsporozoiteclinical trialprotective efficacyimmunogenicity |
| spellingShingle | Helena Nunes-Cabaço Diana Moita Miguel Prudêncio Five decades of clinical assessment of whole-sporozoite malaria vaccines Frontiers in Immunology vaccine plasmodium sporozoite clinical trial protective efficacy immunogenicity |
| title | Five decades of clinical assessment of whole-sporozoite malaria vaccines |
| title_full | Five decades of clinical assessment of whole-sporozoite malaria vaccines |
| title_fullStr | Five decades of clinical assessment of whole-sporozoite malaria vaccines |
| title_full_unstemmed | Five decades of clinical assessment of whole-sporozoite malaria vaccines |
| title_short | Five decades of clinical assessment of whole-sporozoite malaria vaccines |
| title_sort | five decades of clinical assessment of whole sporozoite malaria vaccines |
| topic | vaccine plasmodium sporozoite clinical trial protective efficacy immunogenicity |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.977472/full |
| work_keys_str_mv | AT helenanunescabaco fivedecadesofclinicalassessmentofwholesporozoitemalariavaccines AT dianamoita fivedecadesofclinicalassessmentofwholesporozoitemalariavaccines AT miguelprudencio fivedecadesofclinicalassessmentofwholesporozoitemalariavaccines |